Initial Testing (Stage 1) of the Antibody-Maytansinoid Conjugate, IMGN901 (Lorvotuzumab Mertansine), by the Pediatric Preclinical Testing Program

BACKGROUND: IMGN901 (lorvotuzumab mertansine) is an antibody-drug conjugate composed of a humanized antibody that specifically binds to CD56 (NCAM, neural cell adhesion molecule) and that is conjugated to the maytansinoid, DM1 (a microtubule targeting agent). PROCEDURES: IMGN901 and DM1-SMe (unconju...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Main Authors: Wood, Andrew C., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Wu, Jianrong, Kurmasheva, Raushan T., Whiteman, Kathleen, Houghton, Peter J., Smith, Malcolm A.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4260400/
https://ncbi.nlm.nih.gov/pubmed/23798344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24647
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares